673 related articles for article (PubMed ID: 26386814)
1. Uric acid lowering therapy in cardiovascular diseases.
Volterrani M; Iellamo F; Sposato B; Romeo F
Int J Cardiol; 2016 Jun; 213():20-2. PubMed ID: 26386814
[TBL] [Abstract][Full Text] [Related]
2. Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure.
Borghi C; Palazzuoli A; Landolfo M; Cosentino E
Heart Fail Rev; 2020 Jan; 25(1):43-51. PubMed ID: 31745840
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function.
Bove M; Cicero AFG; Borghi C
Curr Hypertens Rep; 2017 Oct; 19(12):95. PubMed ID: 29071435
[TBL] [Abstract][Full Text] [Related]
4. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study.
Kim SC; Schneeweiss S; Choudhry N; Liu J; Glynn RJ; Solomon DH
Am J Med; 2015 Jun; 128(6):653.e7-653.e16. PubMed ID: 25660249
[TBL] [Abstract][Full Text] [Related]
5. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia.
Bove M; Cicero AF; Veronesi M; Borghi C
Vasc Health Risk Manag; 2017; 13():23-28. PubMed ID: 28223818
[TBL] [Abstract][Full Text] [Related]
6. [Gout and cardiovascular risk].
Němec P
Vnitr Lek; 2014 Oct; 60(10):893-901. PubMed ID: 25382012
[TBL] [Abstract][Full Text] [Related]
7. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
8. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
[TBL] [Abstract][Full Text] [Related]
9. Effects of serum uric acid on blood-pressure lowering treatment.
Grassi G
Curr Med Res Opin; 2017 Nov; 33(sup3):15-19. PubMed ID: 28952389
[TBL] [Abstract][Full Text] [Related]
10. Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S50-6. PubMed ID: 21654270
[TBL] [Abstract][Full Text] [Related]
11. Association of hyperuricemia and serum uric acid lowering therapy with mortality in hemodialysis patients.
Rohn B; Jansing W; Seibert FS; Pfab T; Cinkilic O; Paßfall J; Schmidt S; Babel N; Bauer F; Westhoff TH
Ren Fail; 2020 Nov; 42(1):1067-1075. PubMed ID: 33076736
[TBL] [Abstract][Full Text] [Related]
12. Hyperuricemia and adverse outcomes in cardiovascular disease: potential for therapeutic intervention.
Gavin AR; Struthers AD
Am J Cardiovasc Drugs; 2003; 3(5):309-14. PubMed ID: 14728064
[TBL] [Abstract][Full Text] [Related]
13. Serum uric acid and the risk of cardiovascular and renal disease.
Borghi C; Rosei EA; Bardin T; Dawson J; Dominiczak A; Kielstein JT; Manolis AJ; Perez-Ruiz F; Mancia G
J Hypertens; 2015 Sep; 33(9):1729-41; discussion 1741. PubMed ID: 26136207
[TBL] [Abstract][Full Text] [Related]
14. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
[TBL] [Abstract][Full Text] [Related]
15. Why focus on uric acid?
Johnson RJ
Curr Med Res Opin; 2015; 31 Suppl 2():3-7. PubMed ID: 26414730
[TBL] [Abstract][Full Text] [Related]
16. Xanthine Oxidase and its Role as Target in Cardiovascular Disease: Cardiovascular Protection by Enzyme Inhibition?
Schuchardt M; Herrmann J; Tolle M; van der Giet M
Curr Pharm Des; 2017; 23(23):3391-3404. PubMed ID: 28413972
[TBL] [Abstract][Full Text] [Related]
17. Impact of anti-inflammatory therapies, xanthine oxidase inhibitors and other urate-lowering therapies on cardiovascular diseases in gout.
Richette P; Frazier A; Bardin T
Curr Opin Rheumatol; 2015 Mar; 27(2):170-4. PubMed ID: 25594854
[TBL] [Abstract][Full Text] [Related]
18. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us?
Baker JF; Krishnan E; Chen L; Schumacher HR
Am J Med; 2005 Aug; 118(8):816-26. PubMed ID: 16084170
[TBL] [Abstract][Full Text] [Related]
19. The role of urate-lowering treatment on cardiovascular and renal disease: evidence from CARES, FAST, ALL-HEART, and FEATHER studies.
Pontremoli R
Curr Med Res Opin; 2017 Nov; 33(sup3):27-32. PubMed ID: 28952388
[TBL] [Abstract][Full Text] [Related]
20. Improving cardiovascular and renal outcomes in gout: what should we target?
Richette P; Perez-Ruiz F; Doherty M; Jansen TL; Nuki G; Pascual E; Punzi L; So AK; Bardin T
Nat Rev Rheumatol; 2014 Nov; 10(11):654-61. PubMed ID: 25136785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
